Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 658

1.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.

2.

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Baldetorp B, Borg A.

Breast Cancer Res. 2011;13(6):R129. doi: 10.1186/bcr3075. Epub 2011 Dec 14.

3.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

4.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.

Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS.

Lab Invest. 2008 May;88(5):491-503. doi: 10.1038/labinvest.2008.19. Epub 2008 Mar 10.

5.

Genome profiling of ERBB2-amplified breast cancers.

Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M.

BMC Cancer. 2010 Oct 8;10:539. doi: 10.1186/1471-2407-10-539.

6.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W.

Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.

7.

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M.

BMC Cancer. 2010 Jul 28;10:396. doi: 10.1186/1471-2407-10-396.

8.

High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.

Karlsson E, Waltersson MA, Bostner J, Pérez-Tenorio G, Olsson B, Hallbeck AL, Stål O.

Genes Chromosomes Cancer. 2011 Oct;50(10):775-87. doi: 10.1002/gcc.20900. Epub 2011 Jul 11.

PMID:
21748818
9.

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

J Clin Oncol. 2010 Apr 10;28(11):1813-20. doi: 10.1200/JCO.2009.22.8775. Epub 2010 Mar 15.

PMID:
20231686
10.

New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.

Kauraniemi P, Bärlund M, Monni O, Kallioniemi A.

Cancer Res. 2001 Nov 15;61(22):8235-40.

11.

High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.

Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, Zaks TZ, Weber BL.

Breast Cancer Res. 2005;7(6):R1186-98. Epub 2005 Nov 24.

12.

Gene copy mapping of the ERBB2/TOP2A region in breast cancer.

Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS.

Genes Chromosomes Cancer. 2004 May;40(1):19-31.

PMID:
15034864
13.

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.

Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ.

Mod Pathol. 2010 Jul;23(7):1029-39. doi: 10.1038/modpathol.2010.84. Epub 2010 May 14.

14.

High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.

Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringnér M, Höglund M, Borg A.

Genes Chromosomes Cancer. 2007 Jun;46(6):543-58.

PMID:
17334996
15.

Aberrations of ERBB2 and TOP2A genes in breast cancer.

Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, Ejlertsen B.

Mol Oncol. 2010 Apr;4(2):161-8. doi: 10.1016/j.molonc.2009.11.001. Epub 2009 Nov 18.

16.

Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast.

Hawthorn L, Luce J, Stein L, Rothschild J.

BMC Cancer. 2010 Aug 27;10:460. doi: 10.1186/1471-2407-10-460.

17.

The genomic profile of HER2-amplified breast cancers: the influence of ER status.

Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS.

J Pathol. 2008 Dec;216(4):399-407. doi: 10.1002/path.2423.

PMID:
18810758
18.

Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?

Petroni S, Addati T, Mattioli E, Caponio MA, Quero C, Rubini V, Giotta F, Simone G.

Arch Pathol Lab Med. 2012 Sep;136(9):993-1000. doi: 10.5858/arpa.2011-0327-OA.

PMID:
22938586
19.

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.

Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Børresen-Dale AL, Pollack JR.

Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40.

PMID:
16897746
20.

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2007 Dec;106(2):181-9. Epub 2007 Jan 27.

PMID:
17260090

Supplemental Content

Support Center